CNTB

Connect Biopharma

0.5854 USD
-0.0452
7.17%
Updated Apr 3, 2:28 PM EDT
1 day
-7.17%
5 days
-27.73%
1 month
-32.92%
3 months
-50.39%
6 months
-60.18%
Year to date
-51.62%
1 year
-72.52%
5 years
-96.83%
10 years
-96.83%
 

About: Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.

Employees: 81

0
Funds holding %
of 7,398 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

27% more funds holding

Funds holding: 11 [Q3] → 14 (+3) [Q4]

3% more capital invested

Capital invested by funds: $4.23M [Q3] → $4.37M (+$143K) [Q4]

0.43% more ownership

Funds ownership: 5.33% [Q3] → 5.76% (+0.43%) [Q4]

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$8
1,267%
upside
Avg. target
$8
1,267%
upside
High target
$8
1,267%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Emily Bodnar
18% 1-year accuracy
29 / 161 met price target
1,267%upside
$8
Buy
Reiterated
1 Apr 2025

Financial journalist opinion

Based on 4 articles about CNTB published over the past 30 days

Neutral
GlobeNewsWire
2 days ago
Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart
– FDA aligned on plan to initiate parallel Phase 2 trials of rademikibart in patients with moderate-to-severe asthma or COPD experiencing an acute exacerbation – – Expect to initiate both trials in Q2 2025 – SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or Connect Biopharma), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced positive feedback from its Type C meeting with the U.S. Food and Drug Administration (FDA), Division of Pulmonology, Allergy, and Critical Care, in the Office of Immunology and Inflammation. “We are pleased to have the FDA's alignment on our two parallel Phase 2 trials evaluating rademikibart in patients experiencing an acute exacerbation of asthma or COPD, an area where no biologic therapies have been approved or systematically studied,” said Barry Quart, Pharm.D.
Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart
Neutral
GlobeNewsWire
2 days ago
Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma
– Rademikibart demonstrated rapid onset of action with significant improvements in lung function observed at one week and maintained through 24 weeks – – In patients with eosinophilic-driven asthma (≥300 eosinophils/µL) receiving rademikibart for 24 weeks, the mean difference from placebo in forced expiratory volume was +420 mL, amongst the largest increases reported for a biologic – SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and Chronic Obstructive Pulmonary Disease (COPD), today announced the online publication of positive results from the global Phase 2 trial of rademikibart in patients with moderate-to-severe uncontrolled asthma in the American Journal of Respiratory and Critical Care Medicine (AJRCCM). These data highlight rademikibart's potential as a novel biologic treatment option for patients with asthma and Type 2 inflammation, demonstrating rapid onset of action, sustained improvement in forced expiratory volume in one second (FEV1), and clinically important reductions in annual exacerbation rates.
Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma
Neutral
GlobeNewsWire
3 days ago
Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update
Strengthened leadership team with key appointments, including Barry Quart, Pharm.D. as CEO, and David Szekeres as President, bringing deep clinical, regulatory, operational and strategic expertise Unveiled rapid clinical development program for rademikibart initially targeting acute care in asthma and COPD; expect to initiate parallel Phase 2 trials in 2Q 2025 with data expected in 2H 2026 Strong balance sheet with cash runway into 2027 and through key clinical catalysts SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD), today reported financial results for the year ended December 31, 2024, and provided a business update.
Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update
Neutral
GlobeNewsWire
5 days ago
Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD), today announced that it received a letter dated March 24, 2025 from the Listings Qualifications Department of the Nasdaq Stock Market LLC (Nasdaq) indicating that, for the last 30 consecutive business days, the bid price for the Company's American Depositary Shares (ADSs) had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(a)(1).
Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Neutral
GlobeNewsWire
1 month ago
Connect Biopharma to Present at Two Upcoming Investor Conferences
SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care in Asthma and Chronic Obstructive Pulmonary Disease (COPD), today announced that company management will participate in the following upcoming conferences: Leerink Partners Global Biopharma Conference Format: Fireside ChatDate: Wednesday, March 12, 2025Time: 1:40 p.m. ETWebcast Link: Register Here H.C.
Connect Biopharma to Present at Two Upcoming Investor Conferences
Neutral
GlobeNewsWire
5 months ago
Attovia Therapeutics Appoints Chief Financial Officer
Steven Chan, an accomplished finance leader, joins Attovia as Chief Financial Officer Steven Chan, an accomplished finance leader, joins Attovia as Chief Financial Officer
Attovia Therapeutics Appoints Chief Financial Officer
Negative
GuruFocus
5 months ago
CNTB Stock Dips Amid Biotech Sector Volatility
Cone Biopharma (CNTB, Financial) experienced a significant stock drop of 5.47%, currently trading at $1.21 per share. The trading volume reached 777 shares, with no notable turnover rate.
CNTB Stock Dips Amid Biotech Sector Volatility
Positive
GuruFocus
6 months ago
CNTB Stock Surges Over 5% Amid Strong Financial Performance
Concordia Biotech (CNTB, Financial) saw a significant increase in its stock price, rising by 5.48%. The stock is currently priced at $1.49 per share with a trading volume of 16,435 shares and a turnover rate of 0.03%.
CNTB Stock Surges Over 5% Amid Strong Financial Performance
Neutral
GlobeNewsWire
6 months ago
Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update
SAN DIEGO, CA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma,” “Connect” or the “Company”), a U.S.-headquartered global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with inflammatory diseases, today reported financial results for the six months ended June 30, 2024 and provided a business update.
Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update
Neutral
GlobeNewsWire
9 months ago
Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum
SAN DIEGO, CA and TIACANG, China, July 01, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today that Barry Quart, Chief Executive Officer, David Szekeres, President and Steven Chan, Chief Financial officer will be hosting one-on-one investor meetings at the Leerink Partners Inflammation and Immunology (I&I) and Metabolism Therapeutics Forum, taking place on July 9-10, 2024 in Boston, MA.
Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum
Charts implemented using Lightweight Charts™